Serplulimab (2) – Hetronifly®
Non-small cell lung cancer, non-squamous, EGFR-, ALK- and ROS-negative, first-line treatment, combination with carboplatin and pemetrexed
Characteristics
| Start date | 01.08.2026 |
|---|---|
| Resolution | 21.01.2027 – active procedure |
| INN | Serplulimab |
| Brand name | Hetronifly® |
| Pharm. company | Accord Healthcare GmbH |
| G-BA Procedure ID | D-1337 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
<< List of all resolutions